Title |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial
|
---|---|
Published in |
Lipids in Health and Disease, October 2012
|
DOI | 10.1186/1476-511x-11-133 |
Pubmed ID | |
Authors |
Gislaine Casanova, Poli Mara Spritzer |
Abstract |
Much attention has been drawn to the deleterious effects of adding progestins to estrogen as hormone therapy (HT) in postmenopausal women. Some widely prescribed progestins have been shown to partially oppose the beneficial effects of estrogens on surrogate markers of cardiovascular disease (CVD) risk. Progestins with higher androgenic activity may interfere with lipid profile and glucose tolerance, and could affect mechanisms of estrogen-induced C-reactive protein (CRP) stimulation. Recent data have shown that norpregnane derivatives, but not micronized progesterone, increase the risk of venous thromboembolism among transdermal estrogens users. The aim of the present study was to assess the effects of combining micronized progesterone with non-oral estrogen therapy on lipid profile and cardiovascular risk factors in a sample of early postmenopausal women. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 81 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 16 | 20% |
Other | 10 | 12% |
Researcher | 8 | 10% |
Student > Postgraduate | 8 | 10% |
Student > Master | 8 | 10% |
Other | 12 | 15% |
Unknown | 19 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 31 | 38% |
Agricultural and Biological Sciences | 10 | 12% |
Nursing and Health Professions | 9 | 11% |
Biochemistry, Genetics and Molecular Biology | 4 | 5% |
Unspecified | 2 | 2% |
Other | 7 | 9% |
Unknown | 18 | 22% |